Phosphorylation of tyrosine residues in proteins is a central regulator of cellular functions and is a process controlled by the generically opposite activities of protein-tyrosine kinases and protein-tyrosine phosphatases (PTPs) 1 (1) . Molecular details of the functions of many protein-tyrosine kinases are known, and tight association between dysregulated protein-tyrosine kinase activity and malignant transformation, among other phenomena, is well established (2, 3) . A prominent case in point is Neu/ErbB2, a protein-tyrosine kinase that is amplified in 20 -30% of breast cancer cases and is associated with poor patient prognosis (reviewed in Refs. 4 and 5) . Studies in cultured cells and in transgenic mouse models of breast cancer have demonstrated that activated Neu is an extraordinarily powerful oncogene in vivo and have provided some molecular details of how Neu transforms (6, 7) .
In recent years, PTPs, which are molecularly, biochemically, and physiologically distinct from protein-tyrosine kinases, have emerged as central regulators of physiological processes. PTPs are a structurally diverse superfamily of transmembranal and non-membrane-associated enzymes, of which several dozen members have been identified in organisms ranging from viruses to man (8, 9) . As many oncogenes are tyrosine kinases, it is conceptually not surprising that many PTPs have been shown to inhibit cellular transformation (e.g. Refs. 10 -12) . Although this does not rule out participation of PTPs in cellular transformation events, studies carried out in transfected cells have revealed only a small number of PTPs that can perform such a role. This group includes, at present, receptortype PTP␣ (RPTP␣) (13) , which can transform rat embryo fibroblasts by dephosphorylating and activating Src (14) . Also included in this small group are CDC25 (15) and FAP-1, whose down-regulation of Fas-induced apoptosis may aid tumor cells in evading regulatory mechanisms (16, 17) . Identification of additional PTPs that function to support the transformed phenotype of tumor cells is of great importance to better understand the molecular inner workings of tumor cells and to suggest starting points for future therapies.
The PTP⑀ subfamily contains four distinct protein species, all products of a single gene. RPTP⑀ is an integral membrane protein (13, 18) that has been linked to mouse mammary tumorigenesis (see below) (18, 19) and to down-regulation of insulin receptor signaling in cultured cells (20, 21) . Non-receptor-type PTP⑀ (cyt-PTP⑀), which is expressed from the PTP⑀ gene by use of an alternative promoter (22) (23) (24) , is predominantly cytoplasmic, although it can also be found at the cell membrane (25) . cyt-PTP⑀ dephosphorylates the delayed rectifier, voltage-gated potassium channels Kv2.1 and Kv1.5 in Schwann cells, a finding that correlates with severe transient hypomyelination of sciatic nerve axons in young PTP⑀-deficient mice (26) . PTP⑀ also suppresses endothelial cell proliferation (27) , is required for proper functioning of mouse macrophages (28) , and inhibits JAK (Janus kinase)-STAT (signal transducers and activators of transcription) signaling in M1 leukemia cells in response to various cytokines (29, 30) . p67 PTP⑀ , which is produced by internal initiation of translation from PTP⑀ mRNAs, and p65 PTP⑀ , which is produced by calpain-mediated proteolytic processing of the larger PTP⑀ forms, are N-terminally truncated forms of PTP⑀ and are exclusively cytosolic. The unique N termini of the four PTP⑀ proteins dictate their distinct subcellular localization patterns and, in turn, their physiological roles (21, 25, 26, 31) .
Expression of RPTP⑀ mRNA and protein is significantly elevated in mouse mammary tumors initiated specifically by Ras or Neu, but not by Myc, Int-2, transforming growth factor-␣, or heregulin (18) . The implications of this finding are not obvious and are consistent with RPTP⑀ playing a role either in promoting Neu-or Ras-mediated transformation or in the cellular response countering it. Experimental evidence linking RPTP⑀ with promoting tumorigenesis was provided by the finding that expression of RPTP⑀ in mammary epithelia of transgenic mice causes massive mammary gland hyperplasia and associated tumorigenesis (19) . The present study expands upon these studies by comparing cells from mammary tumors induced by Neu in wild-type and PTP⑀-deficient mice. Although lack of PTP⑀ does not seem to have major effects on tumor initiation in mice, examination of cells from PTP⑀-deficient tumors revealed that RPTP⑀ is required for maintaining optimal growth rates and morphology of these cells in culture and in vivo following implantation in nude mice. At the molecular level, we show that RPTP⑀ is an in vivo physiological activator of Src, a well established collaborator of Neu in such tumors. The absence of RPTP⑀ in Neu-induced mammary tumor cells reduces Src activity and correlates with major parts of the phenotype of these cells, whereas expression of exogenous Src, RPTP⑀, or the related RPTP␣ can reverse some of these phenotypes. Intriguingly, the effects of lack of RPTP⑀ exist despite expression of RPTP␣ in the tumor cells studied, suggesting that this closely related PTP cannot fully compensate for lack of RPTP⑀. The genetic and biochemical evidence presented here indicates that RPTP⑀ joins the small group of PTPs that support, rather than inhibit, the transformed cell phenotype.
EXPERIMENTAL PROCEDURES
Materials-cDNAs for RPTP⑀, cyt-PTP⑀, c-Src, and Y527F Src were cloned into the pcDNA3 eukaryotic expression vector (Invitrogen) as described (25) . The D302A RPTP⑀ mutant was generated by site-directed mutagenesis and, following sequence verification, cloned into pcDNA3. For retroviral infection studies, cDNAs for chicken c-Src and Y527F Src and mouse RPTP⑀ and RPTP␣ were cloned into the pBABE vector (32) . Primary antibodies used in this study included polyclonal anti-PTP⑀ (18) , monoclonal anti-v-Src (Calbiochem), polyclonal antiphospho-Tyr 416 Src and anti-phospho Tyr 527 Src (BIOSOURCE International, Camarillo, CA), monoclonal anti-ErbB2 (clone 42, Transduction Laboratories), and polyclonal anti-RPTP␣ (serum 5478) (33).
Mouse Studies-Gene-targeted mice lacking PTP⑀ (Ptpre Ϫ/Ϫ mice; C57BL/6Jx129 genetic background) (26) were mated with MMTV-Neu transgenic mice (NF and NK lines; FVB/N genetic background) (6) . Progeny were genotyped and mated among themselves to generate MMTV-Neu mice homozygous for the PTP⑀-null allele (Ptpre Ϫ/Ϫ /Neu mice) as well as Ptpre Ϫ/Ϫ and MMTV-Neu mice for control purposes. Female mice of all genotypes were allowed to mate and nurse pups at will to promote expression of the MMTV-Neu transgene; mice were examined visibly or by palpation twice weekly for the presence of tumors. On occasion, equal numbers (1.5 ϫ 10 6 ) of low-passage tumor cells (see below) were injected in 0.2 ml of phosphate-buffered saline into the left fourth inguinal mammary gland or subcutaneously into the right flank of anesthetized 6 -8-week-old CD1 nude female mice. Mice were killed 15 or 21 days later, and tumors were excised and weighed. Each cell line was assayed two or three times at each site, using three mice each time.
Cell Culture-Tumors were minced in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), 4 mM glutamine, 50 units/ml penicillin G, and 50 g/ml streptomycin. Each culture originated in a tumor from a separate mouse and was established in culture without additional transformation. Cell growth was quantified by seeding 0.5-1 ϫ 10 5 cells in duplicates in six-well plates using the crystal violet method (34) . Experiments were repeated three to four times for each cell line. SYF cells (35) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen), 1 mM sodium pyruvate, and glutamine and antibiotics as indicated above. Cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. Ptpre Ϫ/Ϫ /Neu cells were infected with pBABE-based retroviral vectors and selected for 2 days in 2 g/ml puromycin. Cells were maintained in 1 g/ml puromycin and analyzed for expression, morphology, and growth rates 2 weeks later.
Protein Analysis-Cells were lysed in cold buffer A (50 mM Tris-Cl (pH 7.5), 100 mM NaCl, and 1% Nonidet P-40) supplemented with 0.5 mM sodium pervanadate and protease inhibitors (1 mM N-(␣-aminoethyl)benzenesulfonyl fluoride, 40 M bestatin, 15 M E-64, 20 M leupeptin, and 15 M pepstatin; Sigma). Sodium pervanadate was replaced with 5 mM iodoacetic acid in substrate-trapping experiments. SDS-PAGE, immunoprecipitation, and blotting were as described (31) . Following immunoprecipitation, beads were washed extensively three times with radioimmune precipitation assay buffer (for activity assays) or with buffer A (for substrate-trapping experiments). Experiments were repeated two to five times, and representative blots are shown. In control experiments, where known, graded amounts of protein were subjected to SDS-PAGE and blotting, the intensities of signals obtained were proportional in a linear fashion to the different amounts of antigen loaded on the gel.
Src Activity Assay-Beads carrying Src immunoprecipitated from 1 mg of cell lysates were rinsed in kinase buffer (20 mM MOPS (pH 7.0) and 5 mM MgCl 2 ). Each reaction contained 25 l of kinase buffer to which 1 l (5 Ci) of [␥- 32 P]ATP (3000 Ci/mmol, 10 mCi/ml; Amersham Biosciences) and 5 g of acid-denatured enolase (Sigma) were added. Tubes were incubated at 30°C for 10 or 30 min, during which Src activity was linear with respect to time. Reactions were stopped by adding SDS-PAGE sample buffer and boiling. Samples were electrophoresed and blotted onto membranes as described above. Radioactivity present in Src and enolase was quantified using a phosphorimaging (Fuji BAS 2500); the same blots were then probed with anti-Src antibodies and scanned with a scanning densitometer for normalization of Src activity to the amount of Src present in the immunoprecipitates. Experiments were repeated three to five times.
Cloning of RPTP␣ and Activity Assay-Full-length RPTP␣ cDNA was cloned from the Ptpre Ϫ/Ϫ /Neu cell line 7381 using the ProSTAR Ultra HF reverse transcription-PCR system (Stratagene) and sequenced; the sequence has been deposited in GenBank TM /EBI Data Bank. The RPTP␣ cDNA was cloned into the pcDNA3 vector and transfected into 293 cells, which were then lysed in buffer A supplemented with protease inhibitors. Total phosphatase activity in lysates was assayed in duplicates at 30°C in 96-well plates in reactions containing 100 l of cell lysate (2 g/ml) and 200 l of assay buffer (50 mM MES, 0.5 mM dithiothreitol, 0.5 mg/ml bovine serum albumin, and 10 mM p-nitrophenyl phosphate). Each sample was assayed twice with and without the addition of 0.5 mM sodium pervanadate. Activity was measured by following the increase in absorption at 405 nm for 1 h, during which absorption was linear with time. Tyrosine phosphatase (vanadate-inhibitable) activity was calculated as the difference between activities of a given sample measured with and without pervanadate. RPTP␣ cloned into the pBABE retroviral vector was used to infect Ptpre Ϫ/Ϫ /Neu cells for examination of infected cell morphology as described above. /Neu cells were larger and flatter and proliferated significantly slower than Neu cells (Fig. 1, B and C) . No differences in cell survival or plating efficiencies were observed between Ptpre Ϫ/Ϫ /Neu and Neu tumor cells, indicating that the slower proliferation rate of Ptpre Ϫ/Ϫ /Neu cell cultures was due to slower proliferation of these cells.
RESULTS

Lack of RPTP⑀ Alters the Morphology and Reduces the Growth Rate of Mammary Tumor
The differences in growth rates noted above persisted in vivo following injection of Ptpre Ϫ/Ϫ /Neu or Neu tumor cells into the mammary fat pad or subcutaneously into the flank of nude mice. 15 days following injection, mice were killed, and the tumors were excised and weighed. This experimental approach was preferred to measuring tumor size in live mice following cell injection due to the irregular shape of many tumors and the tendency of mouse mammary tumors to form hollow necrotic centers, leading to overestimation of tumor mass based on the dimensions. Care was taken to inject cells that had been propagated in culture for minimal amounts of time. Ptpre Ϫ/Ϫ /Neu and Neu tumor cells generally formed tumors in vivo, with tumors formed in mammary glands significantly larger than those formed in the flank. Interestingly, tumors that arose from Ptpre Ϫ/Ϫ /Neu cells were significantly smaller than those from Neu cells in both the mammary fat pad (78% smaller) and flank (55% smaller) (Fig. 1C) ; similar results were obtained in separate experiments following a 21-day incubation period (data not shown). Tumors that arose in nude mice lacked any visible signs of necrosis and had clearly succeeded in recruiting blood vasculature, arguing that the reduced growth of Ptpre Ϫ/Ϫ /Neu tumors in nude mice was not due to differences in cell survival or angiogenesis. We conclude that RPTP⑀ assists proper development of Neu-induced tumor cells both in vitro and in vivo following injection into nude mice, and that in its absence cells function more poorly.
Lack of RPTP⑀ Reduces Src Activity and Alters Src Phosphorylation-The fact that lack of RPTP⑀ affected the properties of tumor cells generated by activated Neu but did not block the appearance of tumors suggested that RPTP⑀ affects a collaborator of Neu rather than Neu itself. The Src tyrosine kinase is a known collaborator of Neu in transformation of mouse mammary epithelial cells (36, 37) . As Src can be dephosphorylated and activated by the related RPTP␣ (38, 39), we asked whether lack of RPTP⑀ could affect Src activity in mammary tumor cells, thereby possibly causing the Ptpre Ϫ/Ϫ /Neu phenotype. For this purpose, Src was immunoprecipitated from tumor cells, and its activity was analyzed; measurements revealed a decrease of ϳ50% in Src kinase activity in lysates of Ptpre Ϫ/Ϫ / Neu cells (Fig. 2, A and B) . In agreement, protein blotting experiments using phospho-specific antibodies revealed that Src autophosphorylation at Tyr 416 (numbering as in chicken Src) was reduced by 63%, whereas phosphorylation at its C-terminal inhibitory site Tyr 527 was increased by 51% in Ptpre Ϫ/Ϫ /Neu cells (Fig. 2, C and D) . Both changes in Src phosphorylation are consistent with the measured reduction in Src kinase activity.
To determine whether lack of RPTP⑀ merely correlates with or could be the cause of altered Src phosphorylation and activity in Ptpre Ϫ/Ϫ /Neu cells, we examined the effect of expressing PTP⑀ on Src in transfected cells. Experiments were conducted in SYF mouse embryo fibroblasts (35) , which are genetically deficient in the Src, Yes, and Fyn kinases and which do not express PTP⑀. Coexpression of Src and RPTP⑀ resulted in changes in Src that were opposite from those observed in the RPTP⑀-deficient Ptpre Ϫ/Ϫ /Neu cells. Src activity was increased by 78%; and in agreement, Tyr 416 phosphorylation was increased by 52%, and Tyr 527 phosphorylation was decreased by 27% (Fig. 3, A-C) . Similar results were obtained in cells transfected with Src and RPTP␣ (data not shown), in agreement with previously published studies (14, 40 -42) . These results are consistent with RPTP⑀ preferentially dephosphorylating Src at Tyr 527 , thereby activating the kinase and resulting in increased autophosphorylation at Tyr 416 . Interestingly, cyt-PTP⑀ increased Src activity by 117% and strongly reduced phospho-Tyr 527 levels in transfected SYF cells, although no changes in phospho-Tyr 416 levels were detected (Fig. 3, A-C) . We interpret this as being due to the stronger cyt-PTP⑀ activity in these experiments partially dephosphorylating Src at Tyr 416 , thereby countering autophosphorylation at this site. Note that similar levels of RPTP⑀ and full-length cyt-PTP⑀ were expressed in these cells; p67 PTP⑀ and p65 PTP⑀ , which are more significantly coexpressed with cyt-PTP⑀, are exclusively cytosolic proteins and are not believed to reduce phosphorylation of Src (25, 31) .
Src Interacts with the Active Site of PTP⑀ -Further support for Src being dephosphorylated by RPTP⑀ was provided by a substrate-trapping mutant of the phosphatase. Mutants of this type, which are generated by mutating specific key residues in the catalytic domains of PTPs, are either virtually or entirely catalytically inactive, but typically retain the ability to bind phosphorylated substrates via their catalytic sites (43) . Following coexpression of Src with wild-type RPTP⑀ in SYF cells, Src was immunoprecipitated and blotted to reveal associated RPTP⑀. Small amounts of wild-type RPTP⑀ specifically associated with Src and were not detected in identical experiments in which the primary precipitating anti-Src antibody was omitted (Fig. 4) . Replacing wild-type RPTP⑀ with the trapping mutant D302A RPTP⑀ resulted in significantly more RPTP⑀ being coprecipitated with Src; again, binding was specific and was not detected in the absence of the precipitating antibody (Fig. 4) . Increased binding of D302A RPTP⑀ to Src is consistent with Src interacting with the active site of RPTP⑀ and with Src being a substrate of RPTP⑀. The results presented here strongly suggest that RPTP⑀ can dephosphorylate and activate Src and that lack of RPTP⑀ is the cause of altered phosphorylation and reduced activity of Src in Ptpre Ϫ/Ϫ /Neu cells.
Expression of Src or RPTP⑀ Rescues the Altered Morphology of RPTP⑀-deficient Tumor Cells-We next examined whether added expression of Src in Ptpre
Ϫ/Ϫ /Neu cells could rescue some aspects of the phenotype of these cells, thereby supporting an RPTP⑀/Src phenotype connection. For this purpose, we examined Ptpre Ϫ/Ϫ /Neu cells that had been infected with retroviral vectors for expressing c-Src or constitutively active Src (Y527F). Similar cells infected with an empty vector served as controls in these experiments. c-Src and Y527F Src were detected in infected cells by protein blotting (Fig. 5A) . Expression of exogenous Y527F Src was lower than that of exogenous c-Src possibly due to harmful long-term effects of massive overexpression of this highly active Src mutant or to its enhanced degradation (44) . Cells expressing either c-Src or Y527F Src acquired morphological characteristics found in Neu cells, such as smaller size, denser growth, and a less flattened morphology. These changes were not detected in cells infected with the empty viral vector, indicating that they were indeed caused by exogenous Src (Fig. 5B) . Expression of Y527F Src in Ptpre Ϫ/Ϫ /Neu cells also significantly increased the rate of cell proliferation compared with cells expressing c-Src or infected with the empty vector (Fig. 5C ). Y527F Src appeared to be more effective than c-Src in correcting this phenotype of Ptpre Ϫ/Ϫ / Neu cells, possibly because, in contrast with c-Src, it was constitutively active and did not require activation by RPTP⑀, which was absent from these cells. In a separate series of experiments, the ability of exogenous RPTP⑀ to rescue the phenotype of PTP⑀-deficient tumor cells was examined. As described above, Ptpre Ϫ/Ϫ /Neu cells were infected with retroviral vectors for expressing RPTP⑀; cells infected in parallel with empty vectors served as controls here as well. Expression of RPTP⑀ protein was easily detected (Fig.  6A) , although it was more moderate than that of endogenous RPTP⑀ in Neu cells. Src activity was increased in cells expressing RPTP⑀ by ϳ35%, and phospho-Tyr 527 Src levels were reduced by 27% (data not shown). As seen with cells expressing Src, Ptpre Ϫ/Ϫ /Neu cells expressing RPTP⑀ underwent morphological changes to resemble Neu cells or Ptpre Ϫ/Ϫ /Neu cells expressing Src (Fig. 6B) (Fig. 1A) , expression of RPTP␣ clearly does not prevent the Ptpre Ϫ/Ϫ /Neu cell phenotype or the changes observed in Src activity or phosphorylation. One formally possible explanation for this is that RPTP␣ may have sustained inactivating mutation(s) in Ptpre Ϫ/Ϫ /Neu tumors and was itself inactive. To determine whether this was the case, we used reverse transcription-PCR to clone the RPTP␣ cDNA from Ptpre Ϫ/Ϫ /Neu tumor cells. Examination of the cloned RPTP␣ cDNA revealed that its sequence and, by extension, that of its putative protein product were identical to previously published RPTP␣ sequences (data not shown). Furthermore, when the cloned RPTP␣ cDNA was transfected into 293 cells, it produced an appropriately sized protein that was recognized by anti-PTP␣ antibodies, and total tyrosine phosphatase activity in these cells was significantly increased (Fig. 7) . Expression of exogenous RPTP␣ in Ptpre Ϫ/Ϫ /Neu cells resulted in morpho- logical changes similar to those observed following expression of exogenous RPTP⑀ (Fig. 7C) . Together, these data suggest that the phenotype of Ptpre Ϫ/Ϫ /Neu cells is not due to inactivation of the related RPTP␣ and is more consistent with an inability of endogenous RPTP␣ to sufficiently activate Src in the absence of RPTP⑀.
DISCUSSION
The results presented here indicate that loss of RPTP⑀ reduces Src activity and adversely affects the morphology and proliferation rate of Neu-induced mammary tumor cells, attesting to the central role of this phosphatase in this cell system. The strict correlation observed between these phenotypes and lack of RPTP⑀ expression in cells derived from several independent tumors indicates that lack of RPTP⑀ was the basic cause for the observed phenotypes. These results, together with the ability of RPTP⑀ to cause mammary hyperplasia and tumorigenesis in transgenic mice (19) , place RPTP⑀ among the small group of PTPs that are able to support, rather than inhibit, cellular processes linked to transformation.
The fact that PTP⑀-deficient tumor cells do exist suggests that PTP⑀ targets a collaborator of Neu rather than Neu itself. Several considerations make Src a likely candidate for being a target of RPTP⑀ in this respect. Src family kinases and Neu can interact to promote survival and growth of human breast tumor cells (45) . In addition, endogenous Src is activated and can physically associate with Neu via the SH2 (Src homology 2) domain following transformation of mouse mammary epithelial cells by Neu (46), strongly suggesting that Src collaborates with Neu in this transformation process. Furthermore, overexpression of activated Src in mammary epithelia of transgenic mice results in hyperplasia and tumorigenesis (47) . Importantly, this phenotype is weaker than that observed in transgenic mice expressing activated Neu and is in fact reminiscent of the phenotype of transgenic mice expressing RPTP⑀ (19) . This raises the possibility that reducing activities of either protein may have phenotypes of similar magnitudes in mouse mammary tumor cells. Finally, although it has not been examined in mammary tumors in vivo, the ability of RPTP␣ to activate Src established in (among other systems) fibroblasts from RPTP␣ knockout mice (38, 39) suggested that RPTP⑀ might also be capable of activating Src.
Indeed, the activity of Src in Ptpre Ϫ/Ϫ /Neu cells was reduced by ϳ50%, consistent with its decreased phosphorylation at Tyr 416 and its increased phosphorylation at Tyr 527 . In agreement, opposite changes in Src activity and phosphorylation were noted following overexpression of RPTP⑀ in SYF cells, and the substrate-trapping mutant D302A RPTP⑀ bound and coprecipitated Src from cell lysates. This last finding strongly indicates that physical interactions exist between the catalytic site of RPTP⑀ and Src, although studies on RPTP␣ (42) and RPTP⑀ 2 suggest that Src and RPTP⑀ may interact in additional ways as well. Although falling short of formal proof, the finding that expression of RPTP⑀ or cyt-PTP⑀ in cells reduced the levels primarily of phospho-Tyr 527 Src suggests that this residue is a major target of RPTP⑀. Interestingly, it appears that some of the stronger activity of cyt-PTP⑀ "spilled over" and affected phosphorylation of Src at Tyr 416 . Src activity (as measured in vitro by its ability to autophosphorylate and to transphosphorylate enolase) was increased in this case as well, indicating that increased Src activity might not always be manifest as increases in phospho-Tyr 416 Src levels. Altogether, these experiments indicate that RPTP⑀ is a physiological activator of Src and that the changes in Src activity and phosphorylation in Ptpre Ϫ/Ϫ /Neu cells were most likely caused by loss of RPTP⑀ and did not merely correlate with it. It is intriguing that, although RPTP⑀ and RPTP␣ appear to share an ability to act on Src, changes in Src activity and phosphorylation in Ptpre Ϫ/Ϫ /Neu tumor cells occur despite both cell types expressing large and similar amounts of nonmutated RPTP␣ protein. Although the functional relationship between RPTP␣ and Src has not been examined in mammary tumors, the data suggest that RPTP␣ (and possibly other PTPs such as PTP1B (48)) do activate Src in these cells, but cannot do so sufficiently in the absence of RPTP⑀. In other words, a full complement of Src-activating PTPs is required for sufficient activation of this kinase. The fact that Src is still partially active in the absence of RPTP⑀ and the ability of exogenous RPTP␣ to affect the morphology of Ptpre Ϫ/Ϫ /Neu cells both agree with the above interpretation. Yet, data exist suggesting that the roles of RPTP␣ and RPTP⑀ may not be identical in these tumors. This is supported by the finding that RPTP␣ is typically expressed in more differentiated human breast tumors (49) . RPTP␣ expression might then be associated with a weaker malignant phenotype in breast cancer, the opposite of what we have described here for RPTP⑀. Furthermore, RPTP␣ is strongly expressed in mouse mammary tumors initiated by Ras, Neu, Myc, transforming growth factor-␣, heregulin, and Int-2, whereas expression of RPTP⑀ is strictly limited to tumors initiated by Ras and Neu (18) . In this respect, RPTP␣ is more similar to less related PTPs such as PTP, PTPH1, and LAR than to RPTP⑀; further studies are required to elucidate this issue. Nevertheless, the existence of the PTP⑀-deficient phenotype in Ptpre Ϫ/Ϫ /Neu cells indicates that the absence of RPTP⑀ is not compensated for by other PTPs in this cell system and suggests that similar substrate specificity among PTPs might not always translate into full functional redundancy.
The results presented above suggested that a correlation might be found between Src activity and the Ptpre Ϫ/Ϫ /Neu cell phenotype, raising the possibility that increased expression of Src might rescue some aspects of this phenotype. An assumption inherent to this line of study is that some aspects of the Ptpre Ϫ/Ϫ /Neu phenotype are in fact reversible. This is a nontrivial assumption, as these cells were derived from tumors that had undergone extensive selection in vivo and may have progressed beyond the point of phenotype reversibility. Nonetheless, the altered morphology of Ptpre Ϫ/Ϫ /Neu cells was rescued by constitutively active and by non-mutated Src, as well as by RPTP⑀ and RPTP␣. These results strongly support the interpretation that the altered morphology of Ptpre Ϫ/Ϫ / Neu cells is caused by reduced Src activity, caused, in turn, by lack of RPTP⑀. This is particularly appealing due to extensive connections known to exist between Src and downstream molecules involved in regulating cell adhesion (50) . The reduced growth rate of Ptpre Ϫ/Ϫ /Neu cells was also rescued, but only by constitutively active Src. This may indicate that expression of non-mutated Src or RPTP⑀ does not provide a signal strong enough to increase cell proliferation rates or that this aspect of Ptpre Ϫ/Ϫ /Neu cells is more difficult to reverse than morphology. As all aspects of the Ptpre Ϫ/Ϫ /Neu cell phenotype (including reduced proliferation rates) are ultimately caused by lack of RPTP⑀, it is also formally possible that lack of RPTP⑀ affects proliferation of these cells through a Src-independent mechanism. Additional studies are required to address this issue.
Interestingly, the clear phenotype observed in Ptpre Ϫ/Ϫ /Neu tumor cells was not as prominent when the actual tumorigenesis process in mice was examined, e.g. by following tumor latency. Several factors may contribute to this distinction between the two experimental systems. The different conditions cells encounter in vivo versus in culture may result in increased functional redundancy among PTPs in vivo or in the ability to bypass the consequences of reduced Src activity. Examination of Neu-induced mammary tumorigenesis in mice that lack Src or that are simultaneously deficient in PTP⑀ and additional PTPs will be required to clarify these issues in vivo. One should also note that untransformed mouse mammary epithelium expresses very low amounts of PTP⑀; high amounts of RPTP⑀ are detected only in tumors, and it is not clear at what stage of the transformation process RPTP⑀ expression is increased (18) . At the start of the transformation process, RPTP⑀ expression is therefore low in wild-type mice, in which the PTP⑀ gene is nearly inactive, and is absent in Ptpre Ϫ/Ϫ mice, in which the gene has been destroyed. Consequently, the experimental system used here is best suited for examining the effects of lack of RPTP⑀ on the properties of tumor cells, as we do here, rather than on tumor initiation. Finally, activated Neu is an exceedingly powerful oncogene product in the mouse mammary gland system (6) due to its ability to activate several distinct signaling pathways simultaneously (36, 51) . It is unlikely that inhibition of only one of these pathways (such as Src) would be sufficient to prevent transformation. Detection of the phenotypes associated with loss of RPTP⑀ despite the strength of the Neu oncogene product further underscores the importance of RPTP⑀ in these cells. In this light, loss of RPTP⑀ may have a stronger effect on mammary tumorigenesis induced by a slower and less overwhelming, non-activated allele of Neu, although slower tumor induction may partially overlap with background tumorigenesis in mice, thereby complicating interpretation of such results.
The results presented here suggest that it might be useful under certain circumstances to inhibit Src indirectly via inhibition of PTPs that activate the kinase. A general argument in favor of this strategy is that the few PTPs currently known to activate Src do so by dephosphorylating the kinase at Tyr 527 ; this contrasts with small molecule inhibitors of Src, which typically target its ATP-binding site (e.g. Ref. 52 ). The effects of inhibiting Src via inhibition of PTPs may then be additive or synergistic with direct inhibition of Src, thereby increasing the efficiency of Src inhibition beyond what is possible using Src inhibitors alone. In the case of PTP⑀, expression of this phosphatase in tumors and healthy tissues is significantly more restricted than that of Src. One could then target Src inhibition to specific locations where PTP⑀ is expressed by inhibiting PTP⑀, bypassing the need to engineer tissue or cell specificity into Src inhibitors.
